ClinicalTrials.gov record
Completed Phase 2 Interventional

Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy

ClinicalTrials.gov ID: NCT00760955

Public ClinicalTrials.gov record NCT00760955. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 2:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Study to Evaluate the Efficacy and Safety of 3 Doses of TAK-583 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy

Study identification

NCT ID
NCT00760955
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Takeda
Industry
Enrollment
338 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • TAK-583 Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2006
Primary completion
Jan 31, 2008
Completion
Jan 31, 2008
Last update posted
Jun 21, 2016

2006 – 2008

United States locations

U.S. sites
33
U.S. states
18
U.S. cities
33
Facility City State ZIP Site status
Not listed Mesa Arizona
Not listed Peoria Arizona
Not listed Phoenix Arizona
Not listed Tucson Arizona
Not listed Jonesboro Arkansas
Not listed Huntington Beach California
Not listed La Jolla California
Not listed Los Angeles California
Not listed Pasadena California
Not listed Tustin California
Not listed Largo Florida
Not listed Miami Florida
Not listed New Port Richey Florida
Not listed Palm Beach Gardens Florida
Not listed Sunrise Florida
Not listed West Palm Beach Florida
Not listed Decatur Georgia
Not listed Idaho Falls Idaho
Not listed Chicago Illinois
Not listed Boston Massachusetts
Not listed Ann Arbor Michigan
Not listed Las Vegas Nevada
Not listed Englewood New Jersey
Not listed Buffalo New York
Not listed Staten Island New York
Not listed Greenville North Carolina
Not listed Cleveland Ohio
Not listed Portland Oregon
Not listed Duncansville Pennsylvania
Not listed Dallas Texas
Not listed Houston Texas
Not listed San Antonio Texas
Not listed Norfolk Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00760955, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 21, 2016 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00760955 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →